Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Natera Announces Pricing of Follow-On Offering
12:25am, Thursday, 22'nd Jul 2021
AUSTIN, Texas, July 21, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,5
Natera Launches Proposed Follow-On Offering
05:06pm, Tuesday, 20'th Jul 2021
AUSTIN, Texas, July 20, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) ("Natera"), a pioneer and global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public of
Natera Reports Preliminary Second Quarter 2021 Results
08:46am, Monday, 19'th Jul 2021
AUSTIN, Texas, July 19, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) ("Natera" or the "Company"), a pioneer and global leader in cell-free DNA testing, today reported preliminary results for the
AUSTIN, Texas, July 2, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-
Natera: Leading cfDNA Diagnostics Company Offers Strong Growth And Fair Trading Value
05:18am, Thursday, 01'st Jul 2021
Natera: Leading cfDNA Diagnostics Company Offers Strong Growth And Fair Trading Value
This Explosive Biotech Is Taking On a Huge New Market
11:17am, Wednesday, 30'th Jun 2021
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.
Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China
09:03am, Thursday, 24'th Jun 2021
AUSTIN, Texas and SHENZHEN, China, June 24, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, and BGI Genomics Co., Ltd. , (300676.SZ)
How Natera Is Defending Its Lead in a $15B Cancer-Testing Market
10:33am, Tuesday, 22'nd Jun 2021
Natera pioneered DNA blood tests for cancer remaining after treatment. Rivals like Guardant, Invitae, and Exact Sciences are hot on its heels.
Natera Awarded Advanced Diagnostic Laboratory Test (ADLT) Status for its Signatera® MRD Test From CMS
09:03am, Friday, 18'th Jun 2021
AUSTIN, Texas, June 18, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the Centers for Medicare & Medicaid Services (CMS)
Nature Journal Publishes Prospective, Randomized Study Validating Signatera® for Prediction of Immunotherapy Benefit
11:20am, Wednesday, 16'th Jun 2021
AUSTIN, Texas, June 16, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a new study in Nature, validating the
Naturally Splendid NATERA meat-alternative meals to be served up at select Denny's locations in Canada
09:14am, Friday, 11'th Jun 2021
Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCPINK:NSPDF) (FRA:50N) announced that three of its NATERA meat-alternative entrees will soon be appearing on the menu at select Denny's restaurants in C
Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera
07:03am, Tuesday, 08'th Jun 2021
CAMBRIDGE, Mass. and AUSTIN, Texas, June 8, 2021 /PRNewswire/ -- Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA), today announced the launch of the research use version of FoundationOne
Natera Announces New Prospera™ Data at the ATC 2021 Virtual Connect Conference
09:03am, Friday, 04'th Jun 2021
AUSTIN, Texas, June 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on its latest scientific
Naturally Splendid trims loss in 1Q results, turns focus to higher-margin products like NATERA Plant Based Foods
12:16pm, Tuesday, 01'st Jun 2021
Naturally Splendid Enterprises Ltd (FRA:50N) (CVE:NSP) (OTCPINK:NSPDF) has reported its first-quarter results, revealing a narrowing loss compared to the same period of 2020. The company's net loss wa
Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists
04:52pm, Friday, 28'th May 2021
AUSTIN, Texas, May 28, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attem
